11.06.2026 18:01
A study conducted in the UK revealed that households using GLP-1 weight-loss drugs reduced their grocery spending by £780 million over one year. Seventy-five percent of users reported consuming less chocolate, and 72% said they ate fewer chips.
A study conducted in the UK revealed that households using GLP-1 type weight-loss drugs reduced their grocery spending by 780 million pounds in the year following the start of the medication.
WEIGHT-LOSS DRUG USERS VISIT SUPERMARKETS LESS OFTEN
According to a report by The Guardian, a study by the research firm Worldpanel by Numerator, which surveyed over 11,600 households, highlighted that the rise in use of weight-loss drugs such as Mounjaro and Wegovy is also reflected in household food shopping habits.
The study stated that households with at least one person using GLP-1 drugs spent 780 million pounds less on groceries than expected over the year after starting the medication, compared to similar households without users.
This amount equates to an annual decrease of 418 pounds per household with a weight-loss drug user, compared to households without any users.
According to the study, more than 6.3% of households in the UK have at least one GLP-1 user. This rate was recorded as 4.1% in 2025 and 2.3% in 2024.
THEY NO LONGER ENJOY FOODS OR BEVERAGES THEY ONCE LOVED
In February, when the study was conducted, households with weight-loss injection users purchased 299 million fewer products.
52% of users described their approach to eating as "conscious," indicating that their food consumption is shaped by hunger rather than habit, routine, or restriction.
54% of weight-loss injection users reported having less appetite and fewer thoughts about eating, while 11% said they no longer enjoy foods or beverages they once loved.
75% of users reported consuming less chocolate, and 72% reported eating fewer chips.
DRUGS HAVE FUNDAMENTALLY CHANGED PEOPLE'S RELATIONSHIP WITH FOOD
Chantel Kennaugh, Head of Public Sector and Nutrition at Worldpanel by Numerator, commented on weight-loss injections, stating:
"Once a niche treatment primarily prescribed for type 2 diabetes, these drugs have become a mainstream force in just a few years. Now, 68% of users are taking GLP-1s specifically for weight loss, opening them up to a much wider audience."
Kennaugh noted that these drugs have fundamentally altered people's relationship with food and drink, and their effects are already being felt in the grocery and lifestyle sectors, forcing brands and businesses to adapt quickly.